Chiriac Evelina I, Cerbu Simona, Gorun Florin I, Buhas Liana-Camelia, Oros Razvan, Bogdan Buhas A, Vilceanu Narcis, Popa Zoran L, Citu Cosmin, Csep Andrei
Doctoral School, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ROU.
Department of Radiology and Medical Imaging, "Victor Babes" University of Medicine and Pharmacy, Timisoara, ROU.
Cureus. 2024 Dec 10;16(12):e75452. doi: 10.7759/cureus.75452. eCollection 2024 Dec.
This study investigated the relationship between maternal serum amyloid A (SAA) levels, a biomarker of systemic inflammation, and specific neonatal outcomes in preterm birth (PTB). The study included 66 consecutive pregnant women hospitalized for spontaneous preterm delivery (ranging from 28 to 36 gestational weeks), at the Timisoara Municipal Hospital. The study measured mSAA levels to assess their potential as predictors of fetal outcomes (respiratory distress syndrome [RDS]), as well as their association with APGAR score, neonatal leukocyte count, and C-reactive protein (CRP) levels as indicators of neonatal status and response. SAA levels were measured as part of the study protocol for all participants admitted with spontaneous preterm labor symptoms. The results showed a significant negative correlation between mSAA and APGAR score ( = -0.272, two-tailed -value = 0.027). This finding suggests that elevated maternal inflammation may adversely impact the neonate's condition at birth. Additionally, a moderate positive correlation was observed between SAA and neonatal leukocyte count ( = 0.538, < 0.001), reflecting a neonatal inflammatory response. However, SAA was not a significant predictor for RDS (odds ratio [OR] = 1.005, = 0.31). While these findings are promising, they must be interpreted with caution due to limitations such as the small sample size and the cross-sectional nature of the study design. These results suggest that elevated mSAA levels may be associated with immediate adverse neonatal outcomes, supporting the use of inflammatory biomarkers to identify neonatal risks, but further studies are needed for validation.
本研究调查了全身炎症生物标志物母体血清淀粉样蛋白A（SAA）水平与早产（PTB）中特定新生儿结局之间的关系。该研究纳入了蒂米什瓦拉市立医院66例因自发性早产（孕周28至36周）住院的连续孕妇。该研究测量了母体SAA水平，以评估其作为胎儿结局（呼吸窘迫综合征[RDS]）预测指标的潜力，以及其与作为新生儿状态和反应指标的阿氏评分、新生儿白细胞计数和C反应蛋白（CRP）水平之间的关联。作为研究方案的一部分，对所有出现自发性早产症状入院的参与者测量了SAA水平。结果显示母体SAA与阿氏评分之间存在显著负相关（r = -0.272，双侧P值 = 0.027）。这一发现表明母体炎症加剧可能对新生儿出生时的状况产生不利影响。此外，观察到SAA与新生儿白细胞计数之间存在中度正相关（r = 0.538，P < 0.001），反映了新生儿炎症反应。然而，SAA并不是RDS的显著预测指标（优势比[OR] = 1.005，P = 0.31）。虽然这些发现很有前景，但由于样本量小和研究设计的横断面性质等局限性，必须谨慎解读。这些结果表明母体SAA水平升高可能与直接的不良新生儿结局相关，支持使用炎症生物标志物来识别新生儿风险，但需要进一步研究进行验证。
